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Dissolution media based on bicarbonate buffers closely mimic the environment of intestinal 17 
fluids and thus improve in vitro in vivo correlation compared to phosphate buffers. Purging 18 
gases into the medium is used as a method to stabilise bicarbonate buffers; however, this causes 19 
issues due to the disturbance of the hydrodynamics in the dissolution vessel. The aim of this 20 
study was to develop a novel system to regulate and stabilise the pH of bicarbonate buffers 21 
without purging gases for the application of dissolution testing of enteric coated products. A 22 
novel enclosure system was applied to the USP II dissolution vessel to supply N2 and CO2 23 
gases above the dissolution medium without purging into the solution. Drug release from 24 
enteric coated predinisolone microparticles (216.9 µm), pellets (1.25 mm) and commercially 25 
available tablets was determined in 0.1M HCl and subsequently in pH 6.8 phosphate buffer or 26 
pH 6.2-6.8 bicarbonate buffers generated by titration of the acidic medium in situ using USP 27 
II apparatus.  Supplying N2 at 3-4 bar and CO2 at 0.1 bar were able to increase the pH of the 28 
bicarbonate buffer from pH 6.2 to 6.8 within 45 min and subsequently stabilise the medium pH 29 
at 6.8 ± 0.05 pH units. Enteric coated microparticles showed much faster drug release in the 30 
physiological bicarbonate buffers than tablets and pellets. The novel bicarbonate-based 31 
dissolution system moves forward the application of the physiological bicarbonate buffers for 32 
testing pharmaceutical products to meet compendial requirements.  33 
Key words: enteric coating, biorelevant, dissolution, in vitro testing, bicarbonate 34 
  35 
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1 Introduction  36 
The purposes of in vitro dissolution testing are to discriminate between formulations and to 37 
predict how a dosage form will behave in vivo. Phosphate and other compendial buffers are 38 
generally employed due to their high buffer stability during dissolution testing; however it is 39 
not the main physiological buffer species in the intestine where most oral drugs are absorbed. 40 
The predominant buffer in this region is bicarbonate. The use of bicarbonate buffer-based 41 
media for dissolution testing was proven to provide better prediction to in vivo performance 42 
and discrimination of oral products designed to target different segments of the gastrointestinal 43 
tract (Fadda and Basit, 2005; Liu et al., 2011; Liu and Shokrollahi, 2015). The challenge of 44 
applying bicarbonate buffers is the loss of carbon dioxide (CO2) from the solution causing pH 45 
to rise and leading to poor reproducibility of the dissolution test. 46 
Various methods have been investigated to stabilise bicarbonate buffers including continuous 47 
purging of CO2 into the medium solution, application of a layer of liquid paraffin and complete 48 
sealing of the dissolution vessel to prevent gas escape (Fadda et al., 2009; Liu et al., 2011). A 49 
pHysio-stat® system was developed which uses a pH electrode to monitor the pH of the 50 
dissolution media and a gas diffuser to bubble in CO2 or nitrogen (N2) gases to maintain the 51 
pH of the medium throughout the dissolution test (Garbacz et al., 2013). A similar Auto pH 52 
SystemTM incorporated pH monitoring to control the release of helium (pH increasing) and CO2 53 
(pH decreasing) gases to develop a dynamic bicarbonate buffer-based dissolution system 54 
capable of simulating the real-life pH-gradients in the intestinal lumen (Merchant et al., 2014a; 55 
Merchant et al., 2014b).  56 
Bubbling gases into the dissolution medium causes disruption to the hydrodynamics of the 57 
medium which could affect dissolution rate of certain drugs and thus not meeting compendial 58 
requirements (Garbacz et al., 2013; Merchant et al., 2014b). Gas bubbling could generate 59 
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foaming when biorelevant media are used such as those containing surfactants and Fasted State 60 
Simulated Intestinal Fluid (FASSIF) and Fed State Simulated Intestinal Fluid (FESSIF) (Boni 61 
et al., 2007).  When a two-stage dissolution testing is required, e.g. transferring from pH 1 62 
(stomach) to pH 6.8 (intestine) for testing delayed release (enteric coated) products in USP II 63 
paddle apparatus, the test product (such as enteric coated tablets) needs to be picked up and 64 
transferred from acidic to bicarbonate-based media for a complete media change (Liu and 65 
Shokrollahi, 2015). This is not appropriate for multiparticulates such as pellets and 66 
microparticles which can be lost during the media transfer.  67 
The aim of this study was to develop a novel method of stabilising and regulating the pH of the 68 
bicarbonate buffer without the need of bubbling gases. We also aim to develop a single-vessel 69 
method for media transfer from acidic conditions to bicarbonate buffer eliminating the need of 70 
complete media change for testing enteric-coated products including tablets, pellets and 71 
microparticles.  72 
2 Materials and methods 73 
2.1 Materials 74 
Prednisolone (micronized) was purchased from Sanofi (France). Inert spherical particles of 75 
microcrystalline cellulose (MCC; Cellets® 100 and 1000) were purchased from Pharmatrans 76 
Sanaq AG (Switzerland). Hypromellose (Methocel™ E5) was donated by Colorcon (UK). Talc 77 
(Pharm M) was purchased from Imerys Talc (Italy). Methacrylate polymer Eudragit® L30 D-78 
55 was supplied as free samples by Evonik AG (Germany). Triethyl citrate (TEC) and 79 
magnesium stearate were purchased from Acros Organics (UK) and glycerol monostearate 80 
(GMS) Imwitor® 900K from IOI Oleo GmbH (Germany). Gastric-resistant (enteric polymer 81 
polyvinyl acetate phthalate in the coating) prednisolone 5 mg-dose tablets (batch # PW242; 82 
Actavis Group PTC, UK) were used as commercially available product for comparative 83 
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investigation. FaSSIF/FeSSIF/FaSSGF poweder was purchased from Biorelevant.com. All 84 
reagents for dissolution testing were purchased from Fisher Scientific (UK). 85 
2.2 Regulating the pH of bicarbonate solutions using a novel enclosure system 86 
To overcome the issues associated to bubbling gases to regulate or stabilise the pH of 87 
bicarbonate buffers, we used an enclosure device fitted onto the dissolution vessel (USP I and 88 
II) to facilitate gas diffusion into the dissolution medium containing hydrogen carbonate (Liu 89 
et al., 2019).  Gases, N2 (pH increasing) and CO2 (pH decreasing), were supplied via inlets into 90 
the enclosure system, distributed through a ring-shaped diffuser and released via multiple 91 
outlets pointing vertically (90°) or angled (45°) towards the surface of the dissolution medium 92 
(Fig. 1). The enclosure device comprised a plate attached to a ring-shaped chamber. The plate 93 
contained two apertures which were connected to the gas supply at one end (facing upwards) 94 
and the hollow cavity of the ring-shaped chamber at the other end. At the bottom of the chamber 95 
(opposite the plate), a number of orifices were made to evenly distribute the gases on the 96 
surface of the dissolution medium and to facilitate gas diffusion.  97 
2.3 A single-vessel media change and pH-regulation method 98 
For testing enteric-coated products, a media change is required from acidic medium of 0.1 M 99 
HCl (gastric condition) to pH 6.8 buffer (intestinal condition). When bicarbonate buffer is used, 100 
the acidic medium is usually discharged from the vessel and replaced with the buffer. This is 101 
labour intensive and unsuitable for testing multiparticulate-based products. In this study, we 102 
used a single-vessel media transfer method, whereby the enteric-coated product was first tested 103 
in 700 mL 0.1 M HCl. Once the test is completed, 100 mL of 0.65 M NaOH solution was added 104 
to the HCl solution by pouring directly into the vessel and the pH was adjusted to 2.0 - 3.0 105 
using 1 M HCl or 1 M NaOH. A salt solution (100 mL) containing hydrogen carbonate was 106 
then added to the above medium solution by pouring directly into the vessel to reach the final 107 
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composition of the medium equivalent to a modified Hanks buffer (composition: 108 
63.57 mM NaCl, 5.37 mM KCl, 0.812 mM MgSO4.7H2O, 1.26 mM CaCl2, 109 
0.337 mM Na2HPO4.2H2O, 0.441 mM KH2PO4, 4.17 mM NaHCO3) (Liu et al., 2011). The pH 110 
was adjusted to the desired level (e.g. pH 6.2 or 6.8) using 1 M HCl or 1 M NaOH.  111 
The pH of the dissolution medium was monitored and regulated during dissolution using a pH-112 
monitoring/controlling system (NICO 2000, UK) which regulated the supply of the pH-113 
increasing (N2) and decreasing (CO2) gases through electric valves via the enclosure system 114 
described above. The pH values of the bicarbonate-based media (pH 6.8) were measured at 115 
different locations in the dissolution vessel (bottom, middle and top) to evaluate homogeneity 116 
of gas distribution and uniformity of pH throughout the vessel.  117 
Buffer capacity (𝛽) of the bicarbonate buffer was measured by adding aliquots of 0.1 M HCl 118 
to 100 mL of the buffer solution and was calculated using Equation 1.  119 
𝛽 =  
𝛥𝐴𝐵
𝛥𝑝𝐻
  120 
where ΔAB is the small increment in mol/L of the amount of acid or base added to produce a 121 
pH change of ΔpH in the buffer. Buffer capacity was measured at a pH change of 0.5 units on 122 
addition of the acid. All buffer capacity measurements were conducted in triplicate.  123 
2.4 Compatibility with bio-relevant media 124 
FaSSIF/FeSSIF/FaSSGF powder was added to 900 ml pH 6.8 bicarbonate buffer prepared 125 
using methods described above to obtain Fasted State Simulated Intestinal Fluid (FaSSIF, 126 
2.016 g powder added) or Fed State Simulated Intestinal Fluid (FeSSIF, 10.08 g powder 127 
added). The pH of the bicarbonate buffer was maintained at pH 6.8 ± 0.5 using two methods 128 
by 1) bubbling CO2 and N2 directly into the solution at 0.1 bar and 2) supplying CO2 (0.1 bar) 129 
and N2 (4 bar) through the enclosure device.   130 
    Eq. 1 
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2.5 Preparation of prednisolone-loaded microparticles and pellets 131 
Prednisolone was layered onto microcrystalline cellulose (MCC) cores (Cellets® 100 and 132 
Cellets® 1000) using a fluid bed coater (Mini-Glatt; Glatt GmbH, Germany). The drug-loading 133 
suspension contained prednisolone, hypromellose, talc and deionised water (9.79, 1.04, 1.83 134 
and 87.34 % w/w, respectively). Hypromellose was dissolved in deionised water. Prednisolone 135 
and talc were added to the solution and dispersed for 5 min using a propeller mixer (RZR 2051 136 
control, Heidolph Instruments, Germany) at 750 rpm. The resultant suspension was filtered 137 
through a 250 µm mesh sieve and kept under continuous stirring with a magnetic stirrer during 138 
the drug loading process. The suspension was sprayed through a 0.5 mm nozzle at 2.0 – 2.5 139 
g/min maintaining a 30 ºC product temperature with 46 ºC inlet air temperature. The inlet air 140 
flow rate was 18 ± 0.5 m3/h with 2 bar atomisation pressure. The spray process was completed 141 
once 10 % drug loading was achieved.  142 
2.6 Coating of prednisolone microparticles and pellets 143 
Prednisolone-loaded MCC particles (Cellets® 100 and 1000) were coated with a Eudragit® 144 
L30 D-55 dispersion containing triethyl citrate (10 % w/w), glycerol monostearate (GMS, 5 % 145 
w/w), polysorbate 80 (2 % w/w), and deionised water (all percentages based on dry polymer). 146 
Half of the required deionised water were heated to 75-80 °C and GMS was added to the heated 147 
water under continuous stirring with a magnetic stirrer. Triethyl citrate and polysorbate 80 were 148 
added to the GMS emulsion which was stirred continuously for a further 10 min followed by 149 
homogenisation using a rotor-stator homogeniser (Ultra-Turrax T25, IKA-Werke GmbH, 150 
Germany) at 10,000 rpm and 75-80 °C for 10 min. The remaining half of the deionised water 151 
was added to the hot dispersion under continuous stirring using a magnetic stirrer and allowed 152 
to cool to 30 °C. The resultant dispersion was added to the Eudragit® L 30 D-55 dispersion 153 
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under continuous stirring using a magnetic stirrer and were filtered through a 250 µm mesh 154 
sieve before coating.  155 
The polymer dispersion was sprayed through a 0.5 mm nozzle at 1.0–1.5 g/min maintaining a 156 
25-28 ºC product temperature with 32-40 ºC inlet air temperature. The inlet air flow rate was 157 
set to 19 ± 0.5 m3/hr with 1.5 bar atomisation pressure. Continuous vibration was applied during 158 
the polymer coating processes using a pneumatic linear vibrator (NTS 180 NFL, Netter 159 
Vibration, Germany). During coating process, magnesium stearate was periodically added 160 
(every 15 min, at 0.1 % based on starting cores for each addition) to the coating chamber 161 
through an external feeding port (Mohylyuk et al., 2019). At the end of the coating process the 162 
coated particles were dried for 20 min at 25 °C in the processing chamber. After 10 min of 163 
drying, 1 g of silicon dioxide was added to the coating column through the external feeding 164 
port to separate the free-flowing particles and particles stuck in the Wurster column (Mohylyuk 165 
et al., 2019). The coating weight gains for the pellets and microparticles achieved were 18 % 166 
and 73 % respectively. All polymer-coated particles were cured at 40 °C for 24 hours in an 167 
oven (Heratherm OMS60; Thermo Electron LED GmbH, Germany). 168 
The free flowing particles discharged from the coater were analysed using an analytical sieve 169 
shaker (AS200, Retsch GmbH, Germany) fitted with sieves of mesh sizes 90, 125, 180, 250, 170 
355 and 710 µm. Light microscopy (GXL3230, GT Vision Ltd, England) was used to identify 171 
the size ranges of coated particles that were not agglomerated. The percentage yield of the 172 
coating process was calculated using Equation 2 (Mohylyuk et al., 2019). 173 
% 𝑌𝑖𝑒𝑙𝑑 =
 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑛𝑜𝑛−𝑎𝑔𝑔𝑙𝑜𝑚𝑒𝑟𝑎𝑡𝑒𝑑 𝑓𝑟𝑒𝑒 𝑓𝑙𝑜𝑤𝑖𝑛𝑔 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑐𝑜𝑎𝑡𝑒𝑑 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠
 𝑥 100             Eq. 2 174 
Coating thickness was determined for the pellets and microparticles using light microscopy 175 
(GXL3230, GT Vision Ltd, England). The average particle diameter of 100 uncoated and 176 
coated pellets/particles was measured and the coating thickness was calculated using Equation 177 
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3. Scanning electron microscopy (SEM) images were obtained for the coated microparticles 178 






𝐶𝑜𝑎𝑡𝑖𝑛𝑔 𝑡ℎ𝑖𝑐𝑘𝑛𝑒𝑠𝑠 (µ𝑚) =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝑜𝑓 𝑐𝑜𝑎𝑡𝑒𝑑 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 (µ𝑚)−𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 𝑜𝑓 𝑢𝑛𝑐𝑜𝑎𝑡𝑒𝑑 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠(µ𝑚)
2




The specific surface area (SSA) of pellets and microparticles for 5 mg prednisolone dose was 185 
calculated using Equation 4. To calculate the mass of a single pellet/particle (w), approximately 186 
0.02 g pellets/microparticles were weighed using a 6-point balance and the mass was divided 187 
by the number of particles in the weighed sample (manually counted under light microscopy). 188 
The test was conducted in triplicate.  189 
𝑆𝑆𝐴(𝑚𝑚2)  = (
𝑇𝑜𝑡𝑎𝑙 𝑤𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑜𝑓 5𝑚𝑔 𝑑𝑜𝑠𝑒,𝑚𝑔
𝑊𝑒𝑖𝑔ℎ𝑡 𝑜𝑓 𝑜𝑛𝑒 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒,𝑚𝑔
)  × 𝜋 × 𝐷𝑖𝑎𝑚𝑒𝑡𝑒𝑟2                    Eq. 4 190 
2.7 Drug release tests of enteric-coated microparticles, pellets and tablets 191 
Prednisolone release from enteric-coated microparticles, pellets and tablets was evaluated 192 
using a USP-II apparatus (DIS 6000, Copley Scientific, UK) at 37 ± 0.5 °C with a paddle speed 193 
of 100 rpm. Drug release was tested for 2 h in 700 mL (for media change into bicarbonate 194 
buffer) or 750 mL (for media change into phosphate buffer) of 0.1 M HCl solution and 195 
subsequently in one of the three media: 1) 1000 mL of pH 6.8 phosphate buffer (by adding 250 196 
mL of a 0.2 M solution of trisodium phosphate dodecahydrate in the vessel), 2) 900 mL of pH 197 
6.8 bicarbonate buffer prepared as described in Section 2.3, and 3) pH 6.2-6.8 bicarbonate 198 
buffer where the bicarbonate buffer was prepared as described in Section 2.3 to reach a pH 199 
level of 6.2 and the pH value was gradually increased to pH 6.8 in 45 min by supplying N2 200 
through the enclosure and pH-regulating system. For the preparation of both the phosphate and 201 
bicarbonate buffers, the operations of adding the buffer and adjusting the pH were completed 202 
within 5 min. The bicarbonate-based media were stabilised at pH 6.8 for the required duration 203 
by supplying the pH-regulating gases through the enclosure and pH-regulating system. All 204 
buffer stage tests were performed for a total of 2 h.  205 
The quantity of prednisolone released from the products was determined using a closed loop 206 
pumping system and in-line UV-quantification (T70+, PG Instruments, UK) at a wavelength 207 
of 247 nm. All tests were conducted in triplicate. Drug release lag time (tlag) in the buffer stage 208 
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testing was determined as the x-intercept of steady state phase of drug release in the buffer 209 
tests. Complete drug release (t85) was calculated for drug release in the buffer media by using 210 
the first time point where 85 % drug release was observed.  211 
The dissolution data were analysed by using a two-way ANOVA with 95 % confidence interval 212 
using Microsoft Excel (Microsoft Corporation, Washington, USA). 213 
3 Results 214 
3.1 pH-regulation and media change 215 
The use of the enclosure system allowed the pH of the bicarbonate buffer to be regulated 216 
without substantial disruption to the surface of the media. The design of the enclosure system 217 
allowed gases to be supplied at 90° or 45° to the surface of the media under different pressures. 218 
To simulate the gradual pH increase in the upper small intestine, N2 gas was supplied through 219 
the enclosure system to increase the pH of the bicarbonate-based medium from pH 6.2 to 6.8. 220 
Fig. 2a shows that increasing the pressure of the N2 gas (from 3 to 4 bar) increased the rate of 221 
pH rise and N2 gas supplied vertically (at 90°) was more efficient in increasing the pH than at 222 
45°.  Once the pH value has reached pH 6.8, it was stabilised at pH 6.8 ± 0.05 using CO2 (0.1 223 
bar) and N2 (3-4 bar) through the enclosure system (Fig. 2b). 224 
The single vessel media change was reproducibly achieved from 700 mL 0.1 M HCl to pH 6.18 225 
± 0.10 (n=8) and pH 6.80 ± 0.04 (n=8) bicarbonate buffer using the titration method (Tab. 1). 226 
The final pH of the media was adjusted to pH 6.2 ± 0.05 or pH 6.8 ± 0.05. Tab. 2 shows the 227 
pH values measured at different locations in the dissolution vessel using the pH 6.8 bicarbonate 228 
buffer. The buffer capacities for the pH 6.2 and pH 6.8 bicarbonate buffer after pH adjustment 229 
were 5.04 ± 0.29 mmoles/L/ΔpH and 3.31 ± 0.24 mmoles/L/ΔpH respectively.  230 
13 
 
Bubbling CO2 and N2 gases at 0.1 bar into the pH 6.8 bicarbonate buffer containing FaSSIF 231 
and FeSSIF powder generated foaming in the media. When CO2 (0.1 bar) and N2 (4 bar) gases 232 
were supplied through the enclosure device, no foaming was observed for 1 h.  233 
3.2 Drug release from enteric coated prednisolone microparticles, pellets and tablets 234 
Polymer coating of Eudragit® L30 D-55 was successfully achieved using prednisolone-loaded 235 
microparticles (Cellets® 100, diameter D50 = 160.33 ± 2.09 µm for uncoated cores) and pellets 236 
(Cellets® 1000, diameter D50 = 1140 ± 50 µm for uncoated cores), obtaining yield of 87 % and 237 
100 % respectively. The particle size of polymer coated microparticles and pellets were 216.94 238 
± 0.48 µm and 1199 ± 23 µm respectively. The measured coating thicknesses of microparticles 239 
and pellets were 23.5 and 29.5 µm respectively with no statistical difference between the two 240 
(n=100, p>0.05). The specific surface areas for a 5 mg prednisolone dose were 1453 and 225 241 
mm2 for the microparticles and pellets respectively. Fig. 3 shows the SEM images of coated 242 
microparticles and pellets.  243 
There was very low drug release in 0.1 M HCl for 2 h for the enteric-coated microparticles (0.6 244 
± 0.02 %) and pellets (0.7 ± 0.6 %). For the commercially available prednisolone enteric-coated 245 
tables, 10 ± 1.2 % drug release was detected at the end of the 2 h acid stage test.   246 
In pH 6.8 phosphate buffer, drug release was immediate after 2 h acid treatment for the 247 
microparticles, pellets and tablets (Fig. 4) with no significant differences between all three 248 
formulations (p > 0.05). All formulations reached 85 % drug release within 20 min (Tab. 3). 249 
In pH 6.8 bicarbonate buffer, the drug release lag time and t85 were much longer for pellets and 250 
tablets compared to that in phosphate buffer (significantly different for both p < 0.05) (Fig. 5, 251 
Tab. 3). In comparison, much shorter lag time was shown for the microparticles than pellets 252 
and tablets (significantly different to both p < 0.05) (Fig. 5, Tab. 3). For pellets and tablets, the 253 
drug release lag time and t85 were longer in bicarbonate buffer pH 6.2-6.8 than that in 254 
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bicarbonate buffer pH 6.8 (significantly different for both p < 0.05) (Fig. 6, Tab. 3) and the 255 
microparticles again showed shorter lag time and t85 than pellets and tablets (significantly 256 
different to both p < 0.05) (Fig. 6, Tab. 3).   257 
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4 Discussion 258 
Physiological bicarbonate buffers can provide superior prediction of in vivo behaviour of 259 
certain pharmaceutical products in comparison to compendial phosphate buffers. Several 260 
studies have reported better in vivo in vitro correlations of enteric coated products using 261 
bicarbonate buffers than phosphate buffers (Liu and Shokrollahi, 2015; Merchant et al., 2014b; 262 
Varum et al., 2014). Jede et al showed that using biorelevant bicarbonate buffers improved 263 
prediction of in vivo supersaturation and precipitation of poorly soluble weakly basic drugs 264 
than phosphate buffers (Jede et al., 2019). However, the instability of bicarbonate-based buffers 265 
caused by the evaporation of CO2 gas during the dissolution testing presents a barrier for its 266 
use as an in vitro tool. A progressive increase in media pH was noted during in vitro dissolution 267 
testing using bicarbonate buffers (Garbacz et al., 2014), as explained by Equation 5.  268 
 269 
Bubbling CO2 (g) under the surface of the media compensates this loss and decreases the media 270 
pH, whereas, purging an inert gas e.g. N2, helium or a mixture of these gases with air can 271 
remove the dissolved CO2 in the solution and thus increase media pH (Garbacz et al., 2014). 272 
Applying this concept, automated systems (e.g. the pHysio-stat®, pHysio-grad® and the Auto 273 
pH systemTM) have been made available to provide a practical solution to regulate and stabilise 274 
the pH bicarbonate buffers and to simulate the pH gradients in the human intestinal lumen 275 
(Garbacz et al., 2014; Merchant et al., 2014b). Purging gases using these devices have been 276 
utilised by recent studies applying bicarbonate buffer-based dissolution methods (Jede et al., 277 




There are issues associated with bubbling gases into the bicarbonate-based dissolution media. 279 
Firstly, it causes disturbance to the hydrodynamics of the dissolution media, potentially 280 
affecting the drug release rate. It was suggested that the gas diffuser should be placed in the 281 
upper part of the dissolution medium during purging to minimise the effect on drug release, as 282 
the test samples such as tablets are usually located at the bottom of the dissolution vessel  283 
(Garbacz et al., 2014). However, the extent of the impact of gas sparging on drug release 284 
remains unclear. Boni et al observed greater movements of multiparticulate formulations 285 
(pellets) in the dissolution medium caused by bubbling CO2 into bicarbonate buffers than that 286 
caused by the use of phosphate buffers (Boni et al., 2007), which could potentially increase 287 
drug release rate. Secondly, gas bubbling into bicarbonate buffers can cause foaming when 288 
biorelevant media, e.g. FaSSIF and FeSSIF, were used which contain bile salts and lecithin 289 
(Amaral Silva et al., 2019; Boni et al., 2007). Recently Jede et al reported the use of 290 
“biorelevant bicarbonate buffer” by adding FaSSIF powder into 22.5 mM bicarbonate buffer 291 
with pH regulated using the pHysio-grad® (Jede et al., 2019). The authors did not discuss 292 
whether any foaming was observed.  293 
Boni et al reported a method of supplying CO2 above the bicarbonate solution to maintain the 294 
pH value of the medium during dissolution testing (Boni et al., 2007). This approach was not 295 
effective because of the open design of the conventional dissolution vessel lids for USP I and 296 
USP II apparatus which cannot prevent escape of the supplied gas. Fadda et al. investigated 297 
methods providing complete sealing of the bicarbonate media solution including application of 298 
a layer of liquid paraffin and a complete sealed lid of the dissolution vessel to prevent gas 299 
escape (Fadda et al., 2009). These static methods were effective in stabilising the media pH but 300 
cannot provide dynamic pH regulation. In this study we used a specially designed partial 301 
enclosure system that was fitted onto the dissolution vessel (USP I and USP II) to prevent gas 302 
escape and improve the efficiency of gas supply. Gases (CO2 or N2) were supplied into the gas 303 
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inlet of the device and released via multiple outlets to generate even distribution of the gas 304 
above the dissolution medium and maximise the contact of the gas with the solution. This 305 
effectively created a micro-environment with increased partial pressure of CO2 or N2 to 306 
facilitate gas diffusion into the medium and achieve pH regulation.  307 
The partial pressure of a gas was considered as the amount of gas which can diffuse into a 308 
solution from the surface interface above the liquid (Kotz JC et al., 2012). According to Henry’s 309 
law, the concentration of a gas dissolved in a solvent is proportional to the partial pressure of 310 
the gas (Equation 6) (Henry, 1803).   311 
𝑃𝑖 = 𝐻𝑖𝑗𝑥𝑖                                                                                                                          Eq. 6 312 
Where Pi is the partial pressure of component i in the gas; Hij is the Henry’s law constant for 313 
solute i in solvent j and Xi is the mole fraction of component i in the liquid. As part of Henry’s 314 
law, Dalton’s law describes the partial pressure of a gas in a gas mixture (Equation 7) (Smith 315 
and Missen, 2005): 316 
𝑃𝑖 = 𝑃𝑡𝑜𝑡𝑎𝑙𝑥𝑖                                                                          Eq. 7 317 
Where Pi is the partial pressure, Ptotal is the sum of pressures for the mixture of gases and xi is 318 
the mole fraction of the gas of interest in the total mixture of gases. In this study, the enclosure 319 
system used was not completely sealed and therefore the Ptotal above the dissolution medium 320 
was considered to be constant and equivalent to the atmosphere pressure. The partial pressure 321 
of a given gas above the dissolution medium, e.g. CO2 or N2, was therefore proportional to its 322 
mole fraction in the gas mixture. During dissolution testing, the head space of the dissolution 323 
vessel was initially filled with air, a mixture of the ideal gases N2, oxygen, argon and CO2 plus 324 
water vapour and various trace components. When CO2 or N2 was supplied through the 325 
enclosure system to the head space, the partial pressure of the respective gas increases and thus 326 
increasing its concentration dissolved in the medium.  327 
18 
 
Supplying CO2 through the enclosure system was much more efficient in decreasing the 328 
medium pH (0.1 bar of the gas was used) than supplying N2 in increasing the pH (3-4 bar was 329 
required). The two gases, CO2 and N2, have the same solubility at 37 ºC (0.0014 g/kg) (Smith 330 
and Missen, 2005). However, the dissolved CO2 (aq) interacted with water directly generating 331 
carbonic acid which dissociated and released hydrogen ion resulting in pH decrease (Eq.5). In 332 
comparison, the effect of N2 supply was indirect which functioned by reducing the partial 333 
pressure of CO2 in the gas mixture above the dissolution medium. This in turn decreased the 334 
dissolved CO2 concentration in the medium, moving Equation 5 to the left and thus increasing 335 
the pH. This process was much slower than that related to CO2 supply. Suppling N2 gas at 336 
higher pressure into the enclosure system resulted in faster medium pH increase, which can be 337 
explained by Henry’s law and Dalton’s law. The angle of gas outlet to the surface of the 338 
solution affected the rate of pH change. It is likely that distributing the gas vertically towards 339 
the surface of the medium solution promoted better contact of the gas to the solution than 340 
supplying the gas in an angle. Once diffused through the surface of the media, gases were 341 
homogeneously distributed in the dissolution vessel and the pH values were uniform 342 
throughout the vessel. Preliminary observations showed that bubbling gases into the 343 
bicarbonate buffer incorporating FaSSIF and FeSSIF powder caused foaming which was not 344 
the case when the gases were supplied through the enclosure device, showing compatibility 345 
with biorelevant media.  346 
Compendial dissolution method for testing delayed release (enteric coated) formulations 347 
includes a single-vessel media change from acidic condition (0.1 M HCL) to pH 6.8 phosphate 348 
buffer. No similar method was reported using bicarbonate buffer solutions. In this study we 349 
applied a reproducible method to achieve single-vessel media change for two-stage dissolution 350 
testing in bicarbonate buffers. This method is particularly useful for testing multiparticulate-351 
based pharmaceutical products, including liquids with suspended microparticles, Multi Unit 352 
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Pellet Systems (MUPs), powder for reconstitution and granules in capsules which are 353 
considered suitable for use in paediatric and geriatric patients (Liu et al., 2014). When 354 
bicarbonate buffer is used for testing delayed release formulations, a complete media change 355 
(discarding the acidic medium and replacing with bicarbonate buffer) is usually carried out, 356 
which faced challenges in full recovery of the multiparticulate units during media transfer 357 
especially when USP II (paddle) method is required (Liu and Shokrollahi, 2015). The current 358 
titration method reproducibly increased the medium pH and changed the ionic composition of 359 
the medium from stomach to intestinal conditions with comparable buffer capacities to 360 
previous reports at pH 6.8 and pH 6.2 (Merchant et al., 2014b; Varum et al., 2014).   361 
During gastrointestinal transit, the acidic content arriving from the stomach is neutralized by 362 
bicarbonate secreted into the duodenum by the pancreas, resulting in a drastic increase in the 363 
pH value from the stomach to the duodenum. The luminal pH of the proximal small intestine 364 
usually lies within the range of 5.5 to 7.0, gradually increasing to 6.5-7.5 in the distal ileum 365 
(Evans et al., 1988). The pH gradient in the small intestine determines the time and site of the 366 
dissolution of enteric-coated dosage forms based on pH-dependent coatings. Several authors 367 
have reported simulation of the pH changes in the intestine using in vitro dissolution set up 368 
applying bicarbonate based media (Garbacz et al., 2014; Goyanes et al., 2015b; Merchant et 369 
al., 2014b; Wulff et al., 2015). Recent studies by Karkossa et al. applied in vitro methods 370 
mimicking the in vivo gastrointestinal transits and physiological conditions of individual 371 
subjects (Karkossa and Klein, 2018, 2019).  In comparison to the reported pH-regulation 372 
methods by bubbling gases (Garbacz et al., 2014; Merchant et al., 2014a), the pH response of 373 
the current method using the enclosure system in relation to gas supply was slower because of 374 
the time needed for gas diffusion through the media surface. Whilst the method was effective 375 
in stabilising the pH at a certain level and showed potential in providing pH increase simulating 376 
that of the proximal to mid small intestine, its efficiency and flexibility in providing wider pH 377 
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changes and offering individualised in vitro bio-prediction need to be investigated in future 378 
studies.  379 
The bicarbonate based dissolution method reported in this study enabled the comparison of 380 
drug release from enteric coated prednisolone tablets, pellets and microparticles. Prednisolone 381 
was used as a model drug in this study to demonstrate the effect of changes in dissolution media 382 
on drug release from enteric coated dosage forms. As a neutral compound, prednisolone would 383 
have less effect on the dissolution process of enteric polymers than ionisable compounds. 384 
Similar to previous reports, drug release rates from all three enteric coated dosage forms were 385 
rapid in phosphate buffers with no significant differences between the dissolution profiles 386 
(Amaral Silva et al., 2019; Merchant et al., 2014b; Shibata et al., 2016).  In bicarbonate buffers, 387 
a significant drug release lag time was noted for enteric coated tablets and pellets, which was 388 
again in agreement with published studies (Amaral Silva et al., 2019; Merchant et al., 2014b; 389 
Shibata et al., 2016). It was well documented that the dissolution of enteric polymers containing 390 
carboxylic groups was dependent on the composition of the dissolution media including the 391 
buffer species, molarity and ionic strength (Amaral Silva et al., 2019; Boni et al., 2007; 392 
Karkossa and Klein, 2017; Ozturk et al., 1988; Spitael and Kinget, 1977). Being a much weaker 393 
buffer, the ability of bicarbonate buffer (apparent pKa ~ 6.04) to facilitate the polymer 394 
dissociation is lower than that of phosphate buffer (pKa = 7.19) (Boni et al., 2007). Recently 395 
Al-Gousous et al reported that the effective pKa of bicarbonate in the boundary layer between 396 
the dissolving polymer and water is lower than its reported apparent pKa (Al-Gousous et al., 397 
2019). This could cause poor capability of bicarbonate buffer to remove the hydrogen ions and 398 
maintain the surface pH of the dissolving polymer for the dissolution to continue, which could 399 
further explain the slow dissolution of enteric polymers in bicarbonate buffers leading to long 400 
drug release lag times.  401 
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In contrast to enteric coated tablets and pellets, enteric coated microparticles displayed rapid 402 
drug release (short lag time and fast release rate) in bicarbonate buffers similar to that in the 403 
phosphate buffer. This accelerated drug release from microparticles in bicarbonate buffers may 404 
be explained by the large specific surface area available for polymer dissolution. The specific 405 
surface area of enteric coated microparticles used in this study were 6-7 times higher than that 406 
of pellets, which could lead to proportional increase in polymer dissolution rate according to 407 
Noyes and Whitney equation (Noyes and Whitney, 1897), and thus rapid onset of drug release. 408 
It needs to be pointed out that the enteric polymers used in the commercial tablet (polyvinyl 409 
acetate phthalate) was different from that used in the pellets and microparticles (Eudragit® L 410 
30 D -55). It was reported previously that drug release from prednisolone tablets coated with 411 
different enteric polymers showed varied lag times and longer lag time was observed from 412 
polyvinyl acetate phthalate coated tablets than that from tablets coated with Eudragit® L 30 D 413 
-55 (Liu et al., 2011). However, all tablet formulations showed a minimum of 30 min delay 414 
before the onset of dissolution in bicarbonate buffers (Liu et al., 2011), in agreement with the 415 
findings of the current study. Furthermore, the dissolution processes from enteric coated tablets 416 
and multiparticuates were different. For enteric coated tablets, polymer dissolution in buffer 417 
led to tablet disintegration and subsequent drug release (Ozturk et al., 1988). The pellets and 418 
microparticles used in this study were based on microcrystalline cellulose cores that did not 419 
disintegrate. The onset of drug release could relate to the formation of cracks in the coating 420 
caused by polymer dissolution and thinning of the coating layer (Liu et al., 2009). Unlike the 421 
spherical shape of the multiparticulate cores, tablets are not geometrically spherical, resulting 422 
in variations in coating uniformity on different areas of the tablet. The coating at the edges of 423 
the tablet surface was observed to be thinner than that at the center of the tablet surface, 424 
contributing to faster polymer dissolution in these areas and tablet disintegration (Niwa et al., 425 
2014). These differences in the tablet and multiparticulate formulations make direct 426 
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comparison of their dissolution behaviour a challenge; however, the marked acceleration of 427 
drug release from the microparticle formulation in comparison to pellets and tablets 428 
demonstrated its potential in improving in vivo performance of enteric coated products.  429 
The delayed onset of drug release from enteric coated tablets and pellets in in vitro dissolution 430 
testing using bicarbonate buffers reflects the in vivo performance of these dosage forms. Up to 431 
2 h delays were reported for enteric coated tablets and pellets to disintegrate post gastric 432 
emptying in vivo (Bogentoft et al., 1984; Ebel et al., 1993; HARDY et al., 1987; Liu and Basit, 433 
2010). Clinically, this caused retarded absorption and onset of action of the active ingredient, 434 
or even ineffective therapy, as reported in the cases of enteric coated pancreatic enzymes and 435 
aspirin (Guarner et al., 1993; Jirmář and Widimský, 2018). Research has been carried out in 436 
speeding up the dissolution of enteric coated formulations in the proximal small intestine, for 437 
example the design of a double-coating system (DuoCoatTM) that has a buffered inner coat to 438 
accelerate the dissolution of the outer enteric coating (Liu and Basit, 2010). The findings of 439 
this study showed that microparticles that provide large specific surface areas for dissolution 440 
could be another approach in effective delivery of drugs to the proximal small intestine.  441 
Research has made significant progress in the application of physiological bicarbonate buffers 442 
for in vitro dissolution testing of pharmaceutical products, especially facilitated by the 443 
availability of automated pH regulation systems. Recent development in 3D printing for 444 
personalised and patient-centric medicines has broadened the application of bicarbonate-based 445 
systems on dissolution testing of 3D printed modified release formulations including tablets, 446 
Printlets, Miniprintlets and Caplets (Awad et al., 2019; Fina et al., 2018; Goyanes et al., 2015a; 447 
Goyanes et al., 2016; Goyanes et al., 2015c; Vithani et al., 2019; Wang et al., 2016). However, 448 
current pH-regulation of bicarbonate buffers by bubbling gases can potentially change 449 
hydrodynamics of the dissolution medium and affect the compatibility with bio-relevant media. 450 
The preparation of bicarbonate buffers for media change of the two-stage dissolution testing 451 
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can be tedious and impractical for testing multiparticulate formulations. In this study, we 452 
designed the novel enclosure system that avoided gas bubbling into the medium and the 453 
associated disruption to the hydrodynamics of the testing system, meeting the compendial 454 
requirement. It was compatible with biorelevant media providing wider range of applications 455 
for bicarbonate-based dissolution systems. The single-vessel media change method enabled the 456 
use of bicarbonate buffers for two-stage dissolution testing of delayed release multiparticulate 457 
formulations, which is timely considering the recent progress in developing patient-centric 458 
formulations for paediatric and geriatric patients (Liu and Basit, 2010). Future study will apply 459 
the dissolution system in testing a range of compounds and formulations to evaluate its 460 
potential in providing bio-predictive dissolution for pharmaceutical products.  461 
5. Conclusions 462 
An innovative bicarbonate-buffer solution based dissolution system was successfully 463 
developed which stabilised and regulated the pH of the medium through the novel design of an 464 
enclosure system. The system eliminated the need of bubbling gases to the medium and thus 465 
complied with compendial requirements and was compatible with biorelevant media. Media 466 
change from stomach to intestinal conditions for testing delayed release products was achieved 467 
by titration in a single vessel, facilitating the used of bicarbonate-based media in testing 468 
multiparticulate dosage forms. The new dissolution system enabled the comparison of enteric 469 
coated microparticles with pellets and tablets in bicarbonate buffers. The microparticles 470 
showed much faster drug release (shorter onset time) in the physiological bicarbonate buffer 471 
than tablets and pellets, indicating potential improvement in in vivo performance. 472 
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Figure legends 606 
 607 
Fig. 1. Schematic of enclosure and gas delivery 608 
Fig. 2. pH-regulation through the enclosure system: (a) pH increase from pH 6.2 to 6.8 under 609 
different N2 gas pressures and outlet directions and b) pH stabilisation at pH 6.8 using N2 (3-4 610 
bar) and CO2 (0.1 bar) gases. 611 
Fig. 3. Scanning electron microscopy images of a coated a) microparticle and b) pellet 612 
Fig. 4. Drug release from enteric coated prednisolone formulations in 0.1 M HCl and 613 
subsequently in pH 6.8 phosphate buffer.  614 
Fig. 5. Drug release from enteric coated prednisolone formulations in 0.1 M HCl and 615 
subsequently in pH 6.8 bicarbonate buffer.  616 
Fig. 6. Drug release from enteric coated prednisolone formulations in 0.1 M HCl and 617 
subsequently pH 6.2-6.8 bicarbonate buffer. 618 
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Tab. 1. Repeatability of intermediate and final pH adjustment during media change using 645 





(after NaOH addition) 
Final pH 
(buffer stage) 
1 0.76 2.12 5.99 
2 0.76 2.17 6.11 
3 0.76 2.23 6.16 
4 0.69 2.25 6.28 
5 0.64 2.20 6.28 
6 0.64 2.22 6.30 
7 0.83 2.09 6.11 
8 0.67 2.21 6.17 
Mean 0.72 2.19 6.18 
SD 0.06 0.05 0.10 
 647 
  648 
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Tab. 2. pH measurements at different locations of the dissolution vessel. 649 
Distance from 
bottom of vessel 
1 2 3 Mean SD 
5 cm 6.79 6.81 6.81 6.80 0.01 
9 cm 6.78 6.81 6.81 6.80 0.02 
11 cm 6.78 6.8 6.81 6.80 0.02 
Mean 6.78 6.81 6.81   







Tab. 3. The tlag (min) and t85 (min) from enteric coated prednisolone microparticles, pellets and 654 
tablets in pH 6.8 phosphate buffer, pH 6.8 bicarbonate buffer and pH 6.2 - 6.8 bicarbonate 655 
buffer after acid treatment. 656 
 657 
  658 
 659 
Buffer Solution Microparticles Pellets Tablets 
tlag t85 tlag t85 tlag t85 
pH 6.8 phosphate buffer 0.00 5.00 0.00 20.00 0.00 10.00 
pH 6.8 bicarbonate buffer 2.35 15.00 24.08 45.00 37.09 65.00 
pH 6.2-6.8 bicarbonate buffer 6.26 20.00 33.96 55.00 43.49 80.00 
